
Cue Biopharma fell 83.7% from $17.40 to $2.83, behind the S&P 500's +11.0%. Its worst day was Nov 17 (−79.9%), and its low came Nov 17 at $2.83.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cue Biopharma shares rose 34.8%, while the S&P 500 fell 0.0%.
+34.8% · S&P 500 0.0%
EPS of $0.30 beat the $-2.70 estimate on $21.9M revenue (est. $1.0M).
−12.8% · S&P 500 +0.3%
Story events cover the past 12 months · Times ET
Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.
+71.4% · S&P 500 −0.1%
Cue Biopharma shares rose 40.2%, while the S&P 500 fell 0.2%.
+40.2% · S&P 500 −0.2%
Cue Biopharma shares rose 106.4%, while the S&P 500 rose 0.3%.
+106.4%, the year's best day, on 19M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-1.08 missed the $-0.11 estimate on $5.7M revenue (est. $1.0M).
−9.2% · S&P 500 −1.2%
EPS of $-24.14 missed the $-1.38 estimate on $7.9M revenue (est. $3.0M).
−19.2% · S&P 500 −0.5%
Cue Biopharma closed at its highest level of the year, 117.5% above where the year started.
+10.7% · S&P 500 +0.9%
EPS of $-4.74 missed the $-2.60 estimate on $132,000.00 revenue (est. $1.0M).
−79.9%, the year's worst day · S&P 500 −1.0%
Where it ended: a close of $2.83 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 15, 2027 (EPS est. $-1.97, revenue est. $1.0M).
Nothing in the past 12 months.
All CUE dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CUE and SPY from Benzinga historical bars. Not investment advice.